NCT00275301View on ClinicalTrials.gov

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions
Borderline Personality Disorder
Interventions
DRUG

olanzapine

Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.

Trial Locations (1)

55454

University of Minnesota, Dept of Psychiatry, Minneapolis

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Minnesota

OTHER

NCT00275301 - PET Imaging and Olanzapine Treatment in Borderline Personality Disorder | Biotech Hunter | Biotech Hunter